Key points are not available for this paper at this time.
Currently, no pharmacological therapies treat skeletal muscle insulin resistance in pathological conditions such as type 2 diabetes, age-associated diseases, and cancer. Therefore, there is an unmet need to identify the molecular mechanisms ...The molecular events governing skeletal muscle glucose uptake have pharmacological potential for managing insulin resistance in conditions such as obesity, diabetes, and cancer. With no current pharmacological treatments to target skeletal muscle insulin ...
Adler et al. (Thu,) studied this question.